FACS
MCID: FTL073
MIFTS: 26

Fetal Anticonvulsant Syndrome (FACS)

Categories: Fetal diseases, Rare diseases

Aliases & Classifications for Fetal Anticonvulsant Syndrome

MalaCards integrated aliases for Fetal Anticonvulsant Syndrome:

Name: Fetal Anticonvulsant Syndrome 58
Fetal Antiepileptic Drug Syndrome 58
Fetal Aeds 58
Facs 58

Classifications:

Orphanet: 58  
Developmental anomalies during embryogenesis
Teratologic disorders


External Ids:

ICD10 via Orphanet 33 Q86.8
UMLS via Orphanet 72 C1739111
Orphanet 58 ORPHA370068

Summaries for Fetal Anticonvulsant Syndrome

MalaCards based summary : Fetal Anticonvulsant Syndrome, also known as fetal antiepileptic drug syndrome, is related to fanconi anemia, complementation group c and fanconi anemia, complementation group a. An important gene associated with Fetal Anticonvulsant Syndrome is MTHFR (Methylenetetrahydrofolate Reductase). The drugs Glycerol and Tacrolimus have been mentioned in the context of this disorder. Affiliated tissues include breast, lung and t cells.

Related Diseases for Fetal Anticonvulsant Syndrome

Diseases related to Fetal Anticonvulsant Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 155)
# Related Disease Score Top Affiliating Genes
1 fanconi anemia, complementation group c 11.9
2 fanconi anemia, complementation group a 10.5
3 autosomal recessive disease 10.3
4 neutropenia 10.3
5 dentinogenesis imperfecta type 2 10.3
6 hair whorl 10.2
7 breast cancer 10.1
8 stomatitis 10.1
9 alopecia 10.1
10 anemia, x-linked, with or without neutropenia and/or platelet abnormalities 10.1
11 deficiency anemia 10.1
12 leukemia 10.1
13 neuroblastoma 10.1
14 valproate embryopathy 10.0
15 joint laxity, short stature, and myopia 10.0
16 myopia 10.0
17 autoimmune disease 10.0
18 leukemia, chronic lymphocytic 2 10.0
19 bladder cancer 10.0
20 colorectal cancer 10.0
21 leukemia, chronic lymphocytic 10.0
22 ovarian cancer 10.0
23 leukemia, acute myeloid 10.0
24 pachyonychia congenita 3 10.0
25 allergic hypersensitivity disease 10.0
26 dengue disease 10.0
27 sensory peripheral neuropathy 10.0
28 ischemia 10.0
29 embryonal carcinoma 10.0
30 pancreatic ductal adenocarcinoma 10.0
31 macular retinal edema 10.0
32 myeloid leukemia 10.0
33 diabetic macular edema 10.0
34 epicanthus 9.9
35 neural tube defects 9.9
36 strabismus 9.9
37 autism 9.9
38 astigmatism 9.9
39 asperger syndrome 9.9
40 autism spectrum disorder 9.9
41 suppression amblyopia 9.9
42 amblyopia 9.9
43 ametropic amblyopia 9.9
44 anisometropia 9.9
45 mechanical strabismus 9.9
46 color vision deficiency 9.9
47 alzheimer disease 9.8
48 amyotrophic lateral sclerosis 1 9.8
49 aniridia 1 9.8
50 lymphoma, mucosa-associated lymphoid type 9.8

Graphical network of the top 20 diseases related to Fetal Anticonvulsant Syndrome:



Diseases related to Fetal Anticonvulsant Syndrome

Symptoms & Phenotypes for Fetal Anticonvulsant Syndrome

Drugs & Therapeutics for Fetal Anticonvulsant Syndrome

Drugs for Fetal Anticonvulsant Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 202)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Glycerol Approved, Investigational Phase 4 56-81-5 753
2
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
3
Procaine Approved, Investigational, Vet_approved Phase 4 59-46-1 4914
4
Mycophenolic acid Approved Phase 4 24280-93-1 446541
5
Certolizumab pegol Approved Phase 4 428863-50-7
6
Methotrexate Approved Phase 4 59-05-2, 1959-05-2 126941
7
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
8
Hydroxychloroquine Approved Phase 4 118-42-3 3652
9
Morphine Approved, Investigational Phase 4 57-27-2 5288826
10
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
11
Ticagrelor Approved Phase 4 274693-27-5 9871419
12
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
13 Immunologic Factors Phase 4
14 Insulin, Globin Zinc Phase 4
15 insulin Phase 4
16 Vaccines Phase 4
17 Plerixafor octahydrochloride Phase 4
18 Soy Bean Phase 4
19 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
20 Protein Kinase Inhibitors Phase 4
21 Imatinib Mesylate Phase 4 220127-57-1 123596
22 Neurotransmitter Agents Phase 4
23 Analgesics Phase 4
24 Dopamine Agents Phase 4
25 Dopamine Antagonists Phase 4
26 Narcotics Phase 4
27 Antiemetics Phase 4
28 Analgesics, Opioid Phase 4
29 Gastrointestinal Agents Phase 4
30
Ketorolac Approved Phase 2, Phase 3 66635-83-4, 74103-06-3 3826
31
Tramadol Approved, Investigational Phase 2, Phase 3 27203-92-5 33741
32
Cisplatin Approved Phase 2, Phase 3 15663-27-1 2767 441203 84093
33
Docetaxel Approved, Investigational Phase 2, Phase 3 114977-28-5 148124
34
Clopidogrel Approved Phase 3 113665-84-2, 120202-66-6 60606
35
Atorvastatin Approved Phase 2, Phase 3 134523-00-5 60823
36 Coconut Approved Phase 3
37
Vitamin D3 Approved, Nutraceutical Phase 3 67-97-0 5280795 6221
38
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3 1406-16-2
39 Analgesics, Non-Narcotic Phase 2, Phase 3
40 Cyclooxygenase Inhibitors Phase 2, Phase 3
41 Anti-Inflammatory Agents, Non-Steroidal Phase 2, Phase 3
42 Ketorolac Tromethamine Phase 2, Phase 3
43
Erlotinib Hydrochloride Phase 2, Phase 3 183319-69-9 176871
44 Astragalus Phase 2, Phase 3
45 Purinergic P2Y Receptor Antagonists Phase 3
46 Prasugrel hydrochloride Phase 3 389574-19-0
47 Antimetabolites Phase 2, Phase 3
48 Methacholine Chloride Phase 2, Phase 3
49 Hypolipidemic Agents Phase 2, Phase 3
50 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 172)
# Name Status NCT ID Phase Drugs
1 GCSF Plus Plerixafor as First-line Treatment for Autologous Stem Cells Harvest in Children With Malignant Diseases in Need for High-dose Chemotherapy With Stem Cell Rescue. Unknown status NCT02006225 Phase 4 Plerixafor
2 Fat, Inflammation and Insulin Resistance (FIRE-Study) Unknown status NCT01054989 Phase 4
3 Phase 4 Study: Comparison of Myfortic and Early Rapamycin Conversion vs. Low-Dose Tacrolimus in Preventing Acute Rejection and Chronic Allograft Fibrosis: A Protocol Biopsy Directed Approach Unknown status NCT00896012 Phase 4 Rapamune (sirolimus/rapamycin);Tacrolimus
4 Cell Immunity Response to Vaccination Against Influenza in Patients With Rheumatoid Arthritis Unknown status NCT01002716 Phase 4
5 1-Year Longitudinal Follow-up Study of Serologic Responses to 7-valent Pneumococcal Conjugated Vaccination and Opsonophagocytic Activities for Streptococcus Pneumoniae Among Patients With Human Immunodeficiency Virus Infection Unknown status NCT00885625 Phase 4
6 Imatinib Mesylate Therapy in Systemic Mastocytosis Patients Lacking KIT Mutations Completed NCT01297777 Phase 4 Imatinib Mesylate
7 IL-7 and IL-7R Expression in Peripheral Blood Mononuclear Cells, Peripheral Blood Monocytes or Differentiated Macrophages of Rheumatoid Arthritis Patients With Active vs. Inactive Disease Treated With DMARD and/or CIMZIA Completed NCT02451748 Phase 4 Certolizumab pegol (CDP870, tradename Cimzia)(prefilled syringes at the dose of 200mg);Certolizumab pegol (CDP870, tradename Cimzia)
8 The Effects of Morphine on Loading-dose Ticagrelor in Patients With ST-segment Elevation Myocardial Infarction Before Primary Percutaneous Coronary Interven Tion Recruiting NCT02913469 Phase 4 Morphine;metoclopramide;saline
9 Comparison Between the Effects of Intravenous Morphine, Tramadol and Ketorolac on Stress and Immune Responses in Patients Undergoing Modified Radical Mastectomy Unknown status NCT02449954 Phase 2, Phase 3 Intravenous morphine sulphate;Intravenous tramadol HCL;Intravenous ketorolac tromethamine
10 Efficacy Study of Chinese Medicine on Modulating Immune Alterations in Advanced Stage, Non-small Cell Lung Cancer Patients Receiving 1st Line Doublet Chemotherapy and 2nd Line Target Therapy Unknown status NCT01802021 Phase 2, Phase 3 Astagalus-based Formula: Qingshu-Yiqi-Tang
11 Evaluating the Effects of Music Interventions on Hospitalised People With Dementia Unknown status NCT00448318 Phase 2, Phase 3
12 Vasoactive and Anti-inflammatory Effects of Prasugrel in Acute Coronary Syndrome Completed NCT01774838 Phase 3 Prasugrel;Clopidogrel
13 HLA-DQ2-gliadin Tetramer for Diagnosis of Celiac Disease Completed NCT01100099 Phase 2, Phase 3
14 Determination of the Role of Oxygen on Mechanisms Involved in Ischemia-reperfusion Injury in Suspected Acute Myocardial Infarction by Biomarkers. A Sub Study to the DETO2X-AMI Trial. Completed NCT02290080 Phase 3 Oxygen
15 Randomised Controlled Trial to Evaluate the Effect of Statins on Asthma Control of Patients With Chronic Asthma Completed NCT00126048 Phase 2, Phase 3 Atorvastatin;Placebo
16 Vitamin D3 Supplementation in Polymorphic Light Eruption: Randomized Double-blinded Placebo-controlled Trial Terminated NCT01595893 Phase 3 Oral Vitamin D 3;Miglyol 812 N
17 Mesenchymal Stem Cell Therapy for the Treatment of Severe or Refractory Inflammatory and/or Autoimmune Disorders Unknown status NCT01540292 Phase 1, Phase 2
18 New Immunomodulatory Therapy Strategies in Chronic Reactive Arthritis: Immunostimulation Plus Antibiotic Versus Immunosuppression Plus Antibiotic Versus Conventional Standardtherapy Unknown status NCT00244179 Phase 2 interferon-gamma;infliximab;dmard
19 Clinical and Pharmacological Study With 2B3-101 in Patients With Breast Cancer and Leptomeningeal Metastases Unknown status NCT01818713 Phase 2 2B3-101
20 Treatment With AMD3100 Added to a Mobilizing Regimen of G-CSF to Increase the Number of Peripheral Blood Stem Cells in Patients With Hodgkin's Disease Completed NCT00396201 Phase 2 G-CSF Plus Plerixafor
21 Study of Immune Responses and Safety of Recombinant CD40 Ligand in Patients With X-Linked Hyper IgM Syndrome Completed NCT00001145 Phase 2 Bacteriophage;rhuCD40L;KLH
22 A Complementary Trial of an Immunotherapy Vaccine Against Tumor-Specific EGFRvIII Completed NCT00643097 Phase 2 Temozolomide
23 Phase II Study Using a Myeloablative Lymphocyte Depleting Regimen of Chemotherapy and Intensive Total Body Irradiation Followed by Infusion of Tumor Reactive Lymphocytes and Reconstitution With CD34+ Stem Cells in Metastatic Melanoma Completed NCT00314106 Phase 2 Cyclophosphamide;Fludarabine
24 A Phase I/II Study of the Efficacy and Toxicity of Humanized Anti-Tac (Zenapax(Trademark)) in the Therapy of Tac-Expressing Adult T-Cell Leukemia Completed NCT00001941 Phase 1, Phase 2
25 Phase II Study in Patients With Metastatic Melanoma Using a Non-Myeloablative Lymphocyte Depleting Regimen of Chemotherapy Followed by Infusion of gp100 Reactive Peripheral Blood Lymphocytes (PBL) and High or Low Dose Aldesleukin Completed NCT00665470 Phase 2 Aldesleukin
26 Phase I/II Study of Oral Bexarotene in Combination With Photopheresis for Treatment of Cutaneous T-Cell Lymphoma Completed NCT00306969 Phase 1, Phase 2 bexarotene
27 Autologous Immunomagnetic Selected cd133+ Cells in the Treatment of No-option Critical Limb Ischemia: Clinical and Ceus Assessed Results. Completed NCT01595776 Phase 1, Phase 2
28 Randomized Trial of Cladribine (CdA) With Simultaneous or Delayed Rituximab to Eliminate Hairy Cell Leukemia Minimal Residual Disease Recruiting NCT00923013 Phase 2 Cladribine;Rituximab
29 Concurrent Neoadjuvant Chemoradiotherapy Plus Durvalumab (MEDI4736) in Resectable Stage III NSCLC Recruiting NCT03694236 Phase 1, Phase 2 durvalumab
30 Open Label Clinical Trial to Evaluate the Efficacy of Fecal Microbiota Transplantation in Patients With Alopecia Areata Recruiting NCT04238091 Phase 2 Fecal material transfer therapy;Pre-FMT Antibiotic Cocktail;Bowel Prep
31 SAINT: A Phase 1/2 Study of Safe Amounts of IPLIMUMAB, NIVOLUMAB and TRABECTEDIN as First Line Treatment of Advanced Soft Tissue Sarcoma (STS) Recruiting NCT03138161 Phase 1, Phase 2 Trabectedin;Ipilimumab;Nivolumab
32 Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia Recruiting NCT01059786 Phase 2 Pentostatin;Rituximab;Bendamustine
33 Phase II Trial Evaluating the Safety and Efficacy of Ruxolitinib in Patients With Smoldering and Chronic Adult T-cell Leukemia (ATL) Recruiting NCT01712659 Phase 2 Ruxolitinib;ruxolitinib
34 Donor Regulatory T Cells (Treg) Infusion (DTI) in Patients With Steroid-refractory Chronic Graft-versus-host Disease (GVHD) Recruiting NCT01903473 Phase 2 Rapamycin
35 Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes Recruiting NCT03085771 Phase 2 desferal;Isotonic saline
36 A Phase II Study Using Talimogene Laherparepvec for Inflammatory Breast Cancer (IBC) or Non-IBC Patients With Inoperable Local Recurrence Active, not recruiting NCT02658812 Phase 2
37 Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia Active, not recruiting NCT00924170 Phase 1, Phase 2 LMB-2;Fludarabine;Cyclophosphamide
38 A Phase II Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen in Metastatic Melanoma Terminated NCT00863330 Phase 2
39 A Phase II Study of Cell Transfer Therapy for Metastatic Melanoma Using 41BB Selected Tumor Infiltrating Lymphocytes Plus IL-2 Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Terminated NCT02111863 Phase 2 Aldesleukin;Fludarabine;Cyclophosphamide
40 Phase I/II Study Using a Non-Myeloablative Lymphocyte Depleting Regimen of Chemotherapy Followed by Infusion of Allogeneic Tumor-Reactive Lymphocyte Cell Line DMF5 in Metastatic Melanoma Terminated NCT00924001 Phase 1, Phase 2 DMF5 Melanoma Reactive TIL;Cyclophosphamide;Fludarabine;Aldesleukin
41 Phase II Study in Patients With Metastatic Melanoma Using a Non-Myeloablative Lymphocyte Depleting Regimen of Chemotherapy Followed by Infusion of MART-1 Reactive Peripheral Blood Lymphocytes (PBL) With or Without High Dose Aldesleukin Terminated NCT01495572 Phase 2 Fludarabine;Cyclophosphamide;Aldesleukin;MART-1 Reactive CD8+ PBL
42 Phase I/II: Treatment of Adenovirus and Cytomegalovirus Infection Post Human Allogeneic Stem Cell Transplantation With Short-term Expanded Virus-specific T Cells Withdrawn NCT02702427 Phase 1, Phase 2
43 A Randomised Controlled Trial of Combinating an Immune Modulator Fingolimod With Alteplase Bridging With Mechanical Thrombectomy in Acute Ischemic Stroke Withdrawn NCT02956200 Phase 2 Fingolimod
44 The Effect of Autologous Adipose Mesenchymal Stem Cells in Treatment of Airway Injury in Patients Exposed to Sulfur Mustard Unknown status NCT02749448 Phase 1
45 Phase I Trial of Adenoviral Vector Delivery of the Human Interleukin-12 cDNA by Intratumoral Injection in Patents With Metastatic Breast Cancer Completed NCT00849459 Phase 1
46 Vorinostat (SAHA) and Lenalidomide After Autologous Transplant for Patients With Multiple Myeloma Completed NCT00729118 Phase 1 lenalidomide;vorinostat
47 Leukine (Sargramostim) for Parkinson's Disease Completed NCT01882010 Phase 1 sargramostim;placebo
48 Pilot, Randomized, Open-Label, Two-Way Crossover Comparative Bioavailability Study of 40 mg Delayed Release Oral 6Mercaptopurine Versus 100 mg Purinethol in Patients With Crohns Disease Completed NCT00774982 Phase 1 Delayed Release 6 mercaptopurine;6 Mercaptopurine
49 Phase I Study of the Humanized Mik-Beta-1 Monoclonal Antibody Directed Toward IL-2/IL-15R Beta (CD122) That Blocks IL-15 Action In Patients With Refractory Celiac Disease Completed NCT01893775 Phase 1
50 A PHASE I, OPEN LABEL, DOSE-ESCALATION TRIAL EVALUATING THE SAFETY AND TOLERABILITY OF EF-022 (MODIFIED VITAMIN D BINDING PROTEIN MACROPHAGE ACTIVATOR) IN SUBJECTS WITH ADVANCED SOLID MALIGNANCIES Completed NCT02052492 Phase 1 EF-022 (Modified Vitamin D Binding Protein Macrophage Activator)

Search NIH Clinical Center for Fetal Anticonvulsant Syndrome

Genetic Tests for Fetal Anticonvulsant Syndrome

Anatomical Context for Fetal Anticonvulsant Syndrome

MalaCards organs/tissues related to Fetal Anticonvulsant Syndrome:

40
Breast, Lung, T Cells, Bone, Myeloid, Monocytes, Neutrophil

Publications for Fetal Anticonvulsant Syndrome

Articles related to Fetal Anticonvulsant Syndrome:

(show all 21)
# Title Authors PMID Year
1
Exome sequencing in patients with antiepileptic drug exposure and complex phenotypes. 61
31481360 2020
2
Fetal valproate syndrome: the Irish experience. 61
29396778 2018
3
Development of a core outcome set for epilepsy in pregnancy (E-CORE): a national multi-stakeholder modified Delphi consensus study. 61
27860117 2017
4
Early valproic acid exposure alters functional organization in the primary visual cortex. 61
21215743 2011
5
Intracranial arteriovenous malformation with maternal carbamazepine use. 61
17264463 2007
6
Dysmorphic features: an important clue to the diagnosis and severity of fetal anticonvulsant syndromes. 61
16239295 2006
7
A case of fetal anticonvulsant syndrome with severe bilateral upper limb defect. 61
16676441 2006
8
Characteristics of fetal anticonvulsant syndrome associated autistic disorder. 61
16108456 2005
9
Using current evidence in selecting antiepileptic drugs for use during pregnancy. 61
16059433 2005
10
Interaction between anticonvulsants and human placental carnitine transporter. 61
15009220 2004
11
The importance of monotherapy in pregnancy. 61
12796519 2003
12
Pregnancy in the woman with epilepsy: maternal and fetal outcomes. 61
12528055 2002
13
Ophthalmic findings in fetal anticonvulsant syndrome(s). 61
11986102 2002
14
A clinical study of 57 children with fetal anticonvulsant syndromes. 61
10882750 2000
15
5,10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: a HuGE review. 61
10791559 2000
16
Developing diagnostic criteria for the fetal anticonvulsant syndromes. 61
10775521 2000
17
Fetal anticonvulsant syndrome and mutation in the maternal MTHFR gene. 61
10563481 1999
18
Fetal anticonvulsant syndrome in rats: effects on postnatal behavior and brain amino acid content. 61
4080065 1985
19
Functional palatal incompetence in the fetal anticonvulsant syndrome. 61
6497436 1984
20
[Pharmacotherapy of epilepsy--current problems and controversies]. 61
6418628 1983
21
Fetal anticonvulsant syndrome in rats: dose- and period-response relationships of prenatal diphenylhydantoin, trimethadione and phenobarbital exposure on the structural and functional development of the offspring. 61
6195326 1983

Variations for Fetal Anticonvulsant Syndrome

Expression for Fetal Anticonvulsant Syndrome

Search GEO for disease gene expression data for Fetal Anticonvulsant Syndrome.

Pathways for Fetal Anticonvulsant Syndrome

GO Terms for Fetal Anticonvulsant Syndrome

Sources for Fetal Anticonvulsant Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....